- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT03357757
Avélumab avec acide valproïque dans le cancer associé à un virus (LATENT)
L'essai LATENT : Activation lytique pour améliorer la thérapie dirigée par les néo-antigènes Une étude pour évaluer la faisabilité et l'efficacité de l'utilisation combinée d'avelumab avec de l'acide valproïque pour le traitement du cancer associé à un virus
Up to 20% of all cancers may be associated with a bacterial or viral infection. In some instances, the infection may be one of the reasons why the cancer developed in the first place. One such example is infection with the human papilloma virus (HPV) and the development of cervical or oral cavity cancer.
A viral infection that is chronic may not cause a person symptoms, and may be able to escape detection by a person's own immune system. One of the medications being studied in this clinical trial (Valproic acid) may be able to unmask a chronic viral infection from a person's own immune system, therefore making the virus susceptible to attack by the immune system. In this study Valproic acid is being combined with an immune therapy, Avelumab. Avelumab is an antibody that targets a person's own immune cells, or lymphocytes. Lymphocytes must be activated to fight infections or cancer, but after activation they are deactivated. Avelumab prevents the deactivation of a lymphocyte, in effect "turning off the off-switch." This leads to a re-energizing of a person's immune system, hopefully leading to an attack by the immune system on a person's cancer.
Avelumab is known to be an effective treatment for a variety of cancers, although it has not yet been tested in all cancers. By combining Valproic acid, a treatment which targets the virus that contributed to the development of this type of cancer with Avelumab the investigators hope to enhance the ability of Avelumab to restore the body's own immune defense against the cancer.
Aperçu de l'étude
Statut
Les conditions
- Carcinome épidermoïde du col de l'utérus
- Cancer associé à une infection virale chronique
- p16 SCCHN positif
- p16 Carcinome épidermoïde positif du vagin ou de la vulve
- p16 Carcinome épidermoïde positif du pénis
- p16 Carcinome épidermoïde positif de l'anus ou du canal anal
- EBER Positif PNJ
- Lymphome hodgkinien et non hodgkinien EBER positif
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Cross Cancer Institute
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Patients must be 18 years of age or older.
-
Patients with the following histologically confirmed diagnoses will be eligible for enrolment: p16 positive SCCHN; squamous cell carcinoma of the cervix; p16 positive squamous cell carcinoma of the vagina or vulva; p16 positive squamous cell carcinoma of the penis; p16 positive squamous cell carcinoma of the anus or anal canal; EBER positive NPC; EBER positive Hodgkins and non-hodgkins lymphoma.
-
Note: patients with p16 positive SCC of unknown primary origin meeting the minimum life expectancy and performance status requirements will also be eligible for enrollment, as the majority of these patients may be assumed to represent HPV-associated disease.
-
Patients must be capable of providing consent to enrolment and treatment.
-
Patients with a performance status of ECOG 0-1(51) will be eligible for enrolment (see appendix 1).
-
Measurable disease must be present according to irRECIST criteria(50).
-
Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test at the time of screening.
-
Patients of childbearing / reproductive potential should use highly effective birth control methods, as defined by the investigator, during the study treatment period and for a period of 60 days after the last dose of study drug. A highly effective method of birth control is defined as those that result in low failure rate (i.e. less than 1% per year) when used consistently and correctly.
-
Note: abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard.
-
Female patients who are breast-feeding should discontinue nursing prior to the first dose of study treatment and until 120 days after the last dose of study drug.
-
Absence of any condition hampering compliance with the study protocol and follow- up schedule; those conditions should be discussed with the patient before registration in the trial.
-
The following adequate organ function laboratory values must be met:
-
Hematological:
- Absolute neutrophil count (ANC) >1.5 x109/L
- Platelet count >100 x109/L
- Hemoglobin >9 g/dL (may have been transfused)
-
Renal:
o Estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault formula (or local institutional standard method)
-
Hepatic:
- Total serum bilirubin <1.5x ULN
- AST and ALT <2.5x ULN (or ≤ 5 x ULN for subjects with documented metastatic disease to the liver)
- Serum albumin > 25 g/L
-
Coagulation:
- International Normalized Ratio (INR) <1.5x ULN (unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants)
- Activated Partial Thromboplastin Time (aPTT) <1.5x ULN (unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants)
Exclusion Criteria:
- History of pneumonitis requiring treatment with steroids.
- History of interstitial lung disease.
- Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.
- History of another malignancy or a concurrent malignancy;
- Exceptions include patients who have been disease-free for 5 years, or patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible, for example cervical cancer in situ.
- Active brain metastases or leptomeningeal disease.
- Patients with treated brain metastases that are stable for 6 weeks will be eligible for enrolment.
- Diagnosis of immunodeficiency.
- Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
- Prior organ transplantation including allogenic stem-cell transplantation.
- Known history of human immunodeficiency virus (HIV).
- Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive).
- Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible.
- Patients with hyperthyroidism or hypothyroidism but that are stable on hormone replacement will not be excluded.
- Active infection requiring systemic therapy.
- Vaccination within 4 weeks of the first dose of Avelumab and while on trials is prohibited except for administration of inactivated vaccines.
- Patient will not be eligible if the patient is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor staff directly involved with this trial, unless prospective IRB approval (by chair or designee) is given allowing exception to this criterion for a specific subject.
- Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade > 1); however, alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety risk based on investigator's judgment are acceptable.
- Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v4.03 Grade ≥ 3).
- Other severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Avelumab with VPA
Valproic Acid (VPA, 12.5 mg/kg) once per day and Avelumab (10 mg/kg IV) every 2 weeks for up to 2 years. |
The target serum level for VPA will be between 75 and 100 mcg/mL checked every 2 weeks for the first 6 cycles. 10 mg/kg IV |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Efficacy of Avelumab and VPA
Délai: 1 year after enrolment of last patient
|
• Assessment of the clinical response rate according to the immune-related RECIST criteria (iRECIST) |
1 year after enrolment of last patient
|
|
Proportion of subjects who complete 4 doses of Avelumab in combination with VPA
Délai: 1 year after enrolment of last patient
|
• Feasibility analysis, defined as the proportion of subjects who complete 4 doses of Avelumab in combination with VPA over the total duration of the study. |
1 year after enrolment of last patient
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Identifier des cancers spécifiques associés à des virus comme candidats pour une étude ultérieure
Délai: Jusqu'à la fin des études, jusqu'à 2 ans
|
Jusqu'à la fin des études, jusqu'à 2 ans
|
|
|
Mesure de l'expression du CMH
Délai: Jusqu'à la fin des études, jusqu'à 2 ans
|
Jusqu'à la fin des études, jusqu'à 2 ans
|
|
|
Mesure de l'ADN tumoral acellulaire dans le sang
Délai: Jusqu'à la fin des études, jusqu'à 2 ans
|
Jusqu'à la fin des études, jusqu'à 2 ans
|
|
|
Phénotypage des lymphocytes infiltrant les tumeurs
Délai: Jusqu'à la fin des études, jusqu'à 2 ans
|
Jusqu'à la fin des études, jusqu'à 2 ans
|
|
|
Expression de gènes viraux lytiques
Délai: Jusqu'à la fin des études, jusqu'à 2 ans
|
Jusqu'à la fin des études, jusqu'à 2 ans
|
|
|
Immunophénotypage des lymphocytes T cytotoxiques
Délai: Jusqu'à la fin des études, jusqu'à 2 ans
|
Jusqu'à la fin des études, jusqu'à 2 ans
|
|
|
Séquençage des récepteurs des lymphocytes T
Délai: Jusqu'à la fin des études, jusqu'à 2 ans
|
Jusqu'à la fin des études, jusqu'à 2 ans
|
|
|
Concentration de Hsp90 dans le sérum
Délai: Jusqu'à la fin des études, jusqu'à 2 ans
|
Jusqu'à la fin des études, jusqu'à 2 ans
|
|
|
Overall survival
Délai: 5 years from final study drug dose
|
defined as the time from the date of enrollment to the date of death, whatever the cause. |
5 years from final study drug dose
|
|
Progression free survival
Délai: 5 years from final study drug dose
|
Progression free survival is defined as the time between the date of treatment initiation and the date of disease progression or death (whatever the cause), whichever occurs first. |
5 years from final study drug dose
|
|
Number of participants with adverse events
Délai: Through study completion, up to 2 years
|
• Incidence of adverse events (assessed as the incidence and severity of adverse events, including immune-related adverse events, and the number of discontinuations due to adverse events). |
Through study completion, up to 2 years
|
|
Measurement of Immuno-score
Délai: Through study completion, up to 2 years
|
AffymetriX Micro-array (Immuno-score) |
Through study completion, up to 2 years
|
|
DNA viral load
Délai: Through study completion, up to 2 years
|
DNA Quantitative PCR (viral load) |
Through study completion, up to 2 years
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: John Walker, MD PhD FRCPC, Alberta Health services
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- LATENT
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .